Chinese Journal of Antituberculosis ›› 2013, Vol. 35 ›› Issue (4): 282-285.
Previous Articles Next Articles
Received:
2012-11-26
Online:
2013-04-10
Published:
2013-07-02
. The research progression of tuberculosis vaccine on antigen85 complex[J]. Chinese Journal of Antituberculosis, 2013, 35(4): 282-285.
[1] Rowland R, McShane H. Tuberculosis vaccines in clinical trials. Expert Rev Vaccines,2011,10(5):645-658.[2] 尹文东,于庭,梁艳,等.结核分枝杆菌重组Ag85A、Ag85B蛋白免疫原性的研究.中国实验诊断学,2011,15(10):1618-1621.[3] Lu D, Garcia-Contreras L, Muttil P,et al. Pulmonary immunization using antigen 85-B polymeric microparticles to boost tuberculosis immunity.AAPS J, 2010,12(3):338-347.[4] Giri PK, Verma I, Khuller GK. Adjunct immunotherapy with Ag85 complex proteins based subunit vaccine in a murine model of Mycobacterium tuberculosis infection. Immunotherapy, 2009,1(1):31-37.[5] 黎友伦,罗永艾,王国治.细胞因子及其受体在结核免疫中的作用.国外医学内科学分册,2005,32(4):146-149.[6] 师长宏,范雄林,柏银兰,等.结核分枝杆菌Ag85B-ESAT6 融合蛋白在小鼠体内诱导的免疫应答及其保护力.第四军医大学学报,2004,25 (18):1633-1636. [7] Langermans JA, Doherty TM, Vervenne RA,et al.Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6.Vaccine,2005,23(21):2740-2750.[8] McShane H, Pathan AA, Sander CR, et al.Recombinant mo-dified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.Nat Med,2004,10(11):1240-1244.[9] Scriba TJ, Tameris M, Mansoor N, et al.Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells.Eur J Immunol,2010,40(1):279-290.[10] Aeras, University of Oxford,European, Developing Countries Clinical Trials Partnership (EDCTP). Protective efficacy against tuberculosis (TB) disease, safety, and immunogenicity of MVA85A/AERAS-485 in HIV-infected adults[EB/OL].[2012-11-25].http://clinicaltrials.gov/ct2/show/NCT01151189?term=MVA+85A&rank=2.htm. [11] van Dissel JT, Soonawala D, Joosten SA, et al.Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection.Vaccine,2011,3(29):2100-2109. [12] Aeras, Crucell Holland BV. Safety and immunogenicity of AERAS-402 in HIV-infected, Bacillus Calmerre-Guerin(BCG)-vaccinated adults[EB/OL].[2012-11-15].http://clinicaltrials.gov/ct2/show/NCT01017536?term=AERAS-402&rank=2.htm. [13] Horwitz MA, Harth G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis.Infect Immun,2003,71(4):1672-1679.[14] Hoft DF, Blazevic A, Abate G, et al. A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis,2008,198(10):1491-1501.[15] Sugawara I, Sun L, Mizuno S, et al. Protective efficacy of recombinant BCG Tokyo (Ag85A) in rhesus monkeys (Macaca mulatta) infected intratracheally with H37Rv Mycobacterium tuberculosis. Tuberculosis (Edinb),2009,89(1):62-67. [16] Jain R, Dey B, Dhar N, et al.Enhanced and enduring protection against tuberculosis by recombinant BCG-Ag85C and its association with modulation of cytokine profile in lung.PLoS One,2008,3(12):e3869.[17] Xu Y, Liu W, Shen H, et al.Recombinant Mycobacterium bovis BCG expressing the chimeric protein of antigen 85B and ESAT-6 enhances the Th1 cell-mediated response.Clin Vaccine Immunol,2009,16(8):1121-1126.[18] 王平,王丽梅,张薇,等.结核分枝杆菌Ag85B-ESAT-6融合蛋白重组耻垢分枝杆菌对小鼠的免疫原性研究.中国防痨杂志,2012,34(3):145-149.[19] 张灵霞,吴雪琼,董恩军.四种卡介苗重组疫苗对结核病的预防作用.实用医学杂志,2011,27(12):2115-2117.[20] Chang-hong S, Xiao-wu W, Hai Z, et al.Immune responses and protective efficacy of the gene vaccine expressing Ag85B and ESAT6 fusion protein from Mycobacterium tuberculosis.DNA Cell Biol,2008,27(4):199-207.[21] Fan X, Gao Q, Fu R.Differential immunogenicity and protective efficacy of DNA vaccines expressing proteins of Mycobacterium tuberculosis in a mouse model. Microbiol Res,2009,164(4):374-382.[22] 吴雪琼,李洪敏,史迎昌,等.结核分枝杆菌DNA疫苗抗结核作用的研究.中国生物制品学杂志,2002,1(6):340-345.[23] Liang Y, Wu X, Zhang J, et al.The treatment of mice infected with multi-drug-resistant Mycobacterium tuberculosis using DNA vaccines or in combination with rifampin.Vaccine, 2008,26(35):4536-4540.[24] Liang Y,Wu X,Zhang J,et al.Treatment of multi-drug-resis-tant tuberculosis in mice with DNA vaccines alone or incombination in mice chemotherapeutic drugs.Scand J Immunol,2011,74(1):42-46.[25] 梁艳,吴雪琼,张俊仙,等.结核分枝杆菌Ag85A/ESAT-6嵌合型质粒DNA疫苗和抗结核药物联合治疗小鼠耐药结核病的效果研究.中国防痨杂志,2007,29(5):382-385.[26] 胡静,吴雪琼,王丽华,等.结核分支杆菌Ag85B DNA疫苗构建、免疫原性及其保护效力.科学技术与工程,2006,6(13):1765-1770.[27] Tanghe A, D’Souza S, Rosseels V, et al. Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infect Immun,2001,69(5):3041-3047. |
[1] | Liu Juxiu, Zhang Jianhua, Wen Junjun, Jiang Xiaoshuang. Analysis and trend prediction of Mycobacterium tuberculosis drug resistance in Jilin City [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 348-354. |
[2] | Chen Wei, Li Xue, Liu Xiaoqiu, Li Yuhong, Ni Ni, Zhang Hui, Zhao Yanlin. Interpretation and explanation about the National Tuberculosis Prevention and Control Plan (2024—2030) [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 130-136. |
[3] | Rao Lixin, Wu Zheyuan, Chen Jing, Mao Dan, Liu Xinghang, Shen Xin, Chen Xin. Construction, application and prospect of integrated management information system for tuberculosis prevention and control in Shanghai [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 18-21. |
[4] | Huang Xian, Meng Weiyu, Luo Tao, Zhang Weihua, Li Xinyan, Lai Yanfen, Guo Hongge, Tang Vengkai, Lai Xiaoyu, Li Kefeng, Huang Mingxing. Comparative study and suggestions on the return to school policy of students with tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 998-1005. |
[5] | Li Meng, Gao Qian. New challenges in tuberculosis control: startling new findings on aerosol detection [J]. Chinese Journal of Antituberculosis, 2024, 46(7): 739-742. |
[6] | Fan Xiaolei, Maiwulajiang·Yimamu , Peng Xiaowang, Hu Pengyuan, Wang Yanjie, Alimire·Abulimiti , Mairihaba·Kamili , Wang Senlu, Xiang Yang. Analysis of the incidence and influencing factors of household close contacts of pulmonary tuberculosis patients in Kashgar, Xinjiang Uygur Autonomous Region, 2018—2021 [J]. Chinese Journal of Antituberculosis, 2024, 46(4): 390-396. |
[7] | Wang Chenyuan, Wang Shanshan, Wang Sainan, Shao Ge, Cao Jiayi, Xiong Haiyan, Hu Yi. Evaluation of the effectiveness of cerebrospinal fluid characteristics indicators in assisting rapid screening of tuberculous meningitis [J]. Chinese Journal of Antituberculosis, 2024, 46(3): 311-317. |
[8] | Shu Wei, Guo Yusun, Li Shanshan, Pang Yu, Liu Yuhong, Mei Yang. Analysis of tuberculosis prevalence and control along the China-Proposed Belt and Road Initiative [J]. Chinese Journal of Antituberculosis, 2024, 46(3): 318-324. |
[9] | Xia Lan, Liu Shuang, Li Ting, Lu Jia, Wang Danxia, Zhang Linglin. Analysis of screening of close contacts of pathogenic positive pulmonary tuberculosis patients in Sichuan Province from 2018 to 2022 [J]. Chinese Journal of Antituberculosis, 2024, 46(2): 178-182. |
[10] | Jiang Xiaoying, Liu Jing, Zhang Zhiguo, Zhang Wen, Gao Mengqiu, Yang Xinting, Mi Fengling. Investigation and analysis of 196 newly diagnosed etiologically positive pulmonary tuberculosis patients on knowledge of tuberculosis infection control [J]. Chinese Journal of Antituberculosis, 2024, 46(2): 213-220. |
[11] | Gong Fang, Tan Shouyong, Bao Wanling, Liu Guobiao. Analysis of screening results of close contacts of patients with etiologically negative pulmonary tuberculosis in Yuexiu District,Guangzhou City [J]. Chinese Journal of Antituberculosis, 2024, 46(12): 1485-1489. |
[12] | Wang Xueyu, Shi Wenhui, Li Qi, Jing Wei, Chu Naihui, Nie Wenjuan. Efficacy and safety of Baidiziyin Pill and Shenqiyifei Pill in adjuvant treatment of susceptible pulmonary tuberculosis patients: a national randomized controlled multicenter clinical study [J]. Chinese Journal of Antituberculosis, 2024, 46(11): 1306-1312. |
[13] | Daniel P. Chin, Zheng Zhijie. China can eliminate tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(10): 1185-1187. |
[14] | Sun Huijuan, Chen Wei, Zhao Yanlin. The role of community in tuberculosis prevention and control [J]. Chinese Journal of Antituberculosis, 2024, 46(1): 23-28. |
[15] | Zhou Wenyong, Wen Zexuan, Gao Mengxian, Li Tao, Zhang Hui, Wang Weibing. Prediction of the effectiveness and impact of the free healthcare policy for tuberculosis in China [J]. Chinese Journal of Antituberculosis, 2023, 45(9): 845-856. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||